Please wait while the formulary information is being retrieved.
DANTRIUM (DANTROLENE SODIUM)
- Malignant hyperthermia
- Malignant hyperthermia prevention
- Muscle spasticity of cerebral origin
- Muscle spasticity of spinal origin
- Malignant hyperthermia prevention
- Muscle spasm
- Revonto Intravenous Solution
- Dantrolene Intravenous Solution
- Dantrolene Cap
- Dantrium Intravenous Solution
- Dantrium Capsule
- By Indication
20 mg intravenous solution
- Infuse 2.5 mg/kg over 1 hour(s) by intravenous route 1 1/4 hours before anesthesia
20 mg intravenous solution
- Infuse 2.5 mg/kg over 1 hour(s) by intravenous route 1 1/4 hours before anesthesia
dantrolene 100 mg capsule
- 1 capsule (100 mg) by oral route 3 times per day
dantrolene 25 mg capsule
- 1 capsule (25 mg) by oral route 2 times per day
dantrolene 50 mg capsule
- 1 capsule (50 mg) by oral route 3 times per day
20 mg intravenous solution
- Infuse 2.5 mg/kg over 1 hour(s) by intravenous route 1 1/4 hours before anesthesia
25 mg capsule
- 1 capsule (25 mg) by oral route 2 times per day
50 mg capsule
- 1 capsule (50 mg) by oral route 3 times per day
Malignant hyperthermia
- 4 mg/kg by oral route 3 times per day for 1 day
- 4 mg/kg by oral route 3 times per day for 2 days
- 4 mg/kg by oral route 4 times per day for 1 day
- 4 mg/kg by oral route 4 times per day for 2 days
- 8 mg/kg by oral route 3 times per day for 1 day
- 8 mg/kg by oral route 3 times per day for 2 days
- 8 mg/kg by oral route 4 times per day for 1 day
- 8 mg/kg by oral route 4 times per day for 2 days
Malignant hyperthermia prevention
- 1 mg/kg by oral route 4 times per day for 1 day before surgery
- 1 mg/kg by oral route 4 times per day for 2 days before surgery
- 1 mg/kg by oral route 4 times per day before surgery
- 1.3 mg/kg by oral route 3 times per day for 1 day before surgery
- 1.3 mg/kg by oral route 3 times per day for 2 days before surgery
- 1.3 mg/kg by oral route 3 times per day before surgery
- 2 mg/kg by oral route 4 times per day for 1 day before surgery
- 2 mg/kg by oral route 4 times per day for 2 days before surgery
- 2 mg/kg by oral route 4 times per day before surgery
- 2.67 mg/kg by oral route 3 times per day for 1 day before surgery
- 2.67 mg/kg by oral route 3 times per day for 2 days before surgery
- 2.67 mg/kg by oral route 3 times per day before surgery
- Infuse 2.5 mg/kg over 1 hour(s) by intravenous route 1 1/4 hours before anesthesia
Muscle spasm
- 1 capsule (25 mg) by oral route 2 times per day
- 1 capsule (25 mg) by oral route 3 times per day
- 1 capsule (25 mg) by oral route 4 times per day
- 1 capsule (25 mg) by oral route once daily
- 2 capsules (50 mg) by oral route 2 times per day
- 2 capsules (50 mg) by oral route 3 times per day
- 2 capsules (50 mg) by oral route 4 times per day
- 1 capsule (50 mg) by oral route 2 times per day
- 1 capsule (50 mg) by oral route 3 times per day
- 1 capsule (50 mg) by oral route 4 times per day
- 2 capsules (100 mg) by oral route 3 times per day
- 2 capsules (100 mg) by oral route 4 times per day
- 2 capsules (100 mg) by oral route 2 times per day
Muscle spasticity of cerebral origin
- 1 capsule (50 mg) by oral route 3 times per day
- 1 capsule (50 mg) by oral route 4 times per day
Muscle spasticity of spinal origin
- 1 capsule (50 mg) by oral route 3 times per day
- 1 capsule (50 mg) by oral route 4 times per day
- None
Contraindicated
- Adalat Cc
- Afeditab Cr
- aliskiren-amlodipin-hcthiazide
- aliskiren-amlodipine
- amlodipine
- amlodipine-atorvastatin
- amlodipine-benazepril
- amlodipine-olmesartan
- amlodipine-valsartan
- amlodipine-valsartan-hcthiazid
- Amturnide
- Azor
- Caduet
- Calan
- Calan Sr
- Cardene Iv
- Cardene Iv In Dextrose
- Cardene Iv In Sodium Chloride
- Cardene Sr
- Cardizem
- Cardizem Cd
- Cardizem La
- Cartia Xt
- Dilacor Xr
- Dilt-xr
- diltiazem HCl
- Exforge
- Exforge Hct
- felodipine
- isradipine
- Lotrel
- Matzim La
- nicardipine
- nicardipine in dextrose,iso-os
- nicardipine in NaCl (iso-os)
- Nifedical Xl
- nifedipine
- nimodipine
- nisoldipine
- Norvasc
- Nymalize
- olmesartan-amlodipin-hcthiazid
- Procardia
- Procardia Xl
- Sular
- Tarka
- Taztia Xt
- Tekamlo
- telmisartan-amlodipine
- Tiazac
- trandolapril-verapamil
- Tribenzor
- Twynsta
- verapamil
- Verelan
- Verelan Pm
Severe
Moderate
- None
- Hepatitis
Contraindicated
- Disease of liver
Severe
Moderate
- Chronic obstructive pulmonary disease
- Pulmonary disease
- Severe cardiac disease
DANTRIUM (DANTROLENE SODIUM)
- Malignant hyperthermia
- Malignant hyperthermia prevention
- Muscle spasticity of cerebral origin
- Muscle spasticity of spinal origin
- Malignant hyperthermia prevention
- Muscle spasm
- None
- Dizziness
- Drowsy
- Fatigue
- Malaise
- Muscle weakness
More Frequent
Severe
Less Severe
- Acute confusion
- Allergic dermatitis
- Depression
- Drug-induced hepatitis
- Dysuria
- Hematuria
- Pleural effusions
- Pruritus of skin
- Respiratory depression
- Seizure disorder
- Skin rash
- Urticaria
- Abdominal pain with cramps
- Anorexia
- Chills
- Constipation
- Diarrhea
- Diplopia
- Dysgeusia
- Dysphagia
- Fever
- Headache disorder
- Increased urinary frequency
- Insomnia
- Nausea
- Nervousness
- Urinary incontinence
- Visual changes
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Anaphylaxis
- Anemia
- Aplastic anemia
- Eosinophilia
- Extravasation injury
- Gastrointestinal hemorrhage
- Heart failure
- Jaundice
- Leukopenia
- Malignant lymphoma
- Pericarditis
- Severe diarrhea
- Thrombocytopenic disorder
- Thrombophlebitis
Less Severe
- Abnormal blood pressure
- Acneiform eruption
- Back pain
- Crystalluria
- Erectile dysfunction
- Eye tearing
- Hirsutism
- Hyperhidrosis
- Myalgias
- Tachycardia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Dantrolene (oral)
No long term safety data. Weigh risk-benefit.
- 1 Day – 5 Years
- No long term safety data. Weigh risk-benefit.
Dantrolene (inj)
- Severity Level:
C
- Additional Notes: Insufficient human data; embryo-lethal in rabbits at doses 7x mrhd
Dantrolene (oral)
- Severity Level:
C
- Additional Notes: Insufficient human and animal data
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Dantrolene
Insuff data avail; low levels excreted in milk; potential for infant adv eff
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Insuff data avail; low levels excreted in milk; potential for infant adv eff |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Dantrolene
Hepatic-The risk of hepatic injury appears to be greater in patients at doses over 400mg/day, over 35 years of age, and in patients taking other medication(s) in addition to dantrolene. Spontaneous reports suggest a higher proportion of hepatic events with fatal outcome in elderly patients. Frequent monitoring of LFT's is recommended. Neuro/Psych-Risks for sedation, confusion and cognitive impairment. Fall risk increased.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | Y | Y | Y | Y | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Malignant hyperthermia | |
| T88.3 | Malignant hyperthermia due to anesthesia |
| T88.3xxA | Malignant hyperthermia due to anesthesia, initial encounter |
| Muscle spasm | |
| M62.83 | Muscle spasm |
| M62.830 | Muscle spasm of back |
| M62.831 | Muscle spasm of calf |
| M62.838 | Other muscle spasm |
| R25.2 | Cramp and spasm |
| Muscle spasticity of cerebral origin | |
| M62.83 | Muscle spasm |
| M62.830 | Muscle spasm of back |
| M62.831 | Muscle spasm of calf |
| M62.838 | Other muscle spasm |
| R25.2 | Cramp and spasm |
| Muscle spasticity of spinal origin | |
| M62.83 | Muscle spasm |
| M62.830 | Muscle spasm of back |
| M62.831 | Muscle spasm of calf |
| M62.838 | Other muscle spasm |
| R25.2 | Cramp and spasm |
| 0-9 | A-Z |
|---|---|
| M62.83 | Muscle spasm |
| M62.83 | Muscle spasm |
| M62.83 | Muscle spasm |
| M62.830 | Muscle spasm of back |
| M62.830 | Muscle spasm of back |
| M62.830 | Muscle spasm of back |
| M62.831 | Muscle spasm of calf |
| M62.831 | Muscle spasm of calf |
| M62.831 | Muscle spasm of calf |
| M62.838 | Other muscle spasm |
| M62.838 | Other muscle spasm |
| M62.838 | Other muscle spasm |
| R25.2 | Cramp and spasm |
| R25.2 | Cramp and spasm |
| R25.2 | Cramp and spasm |
| T88.3 | Malignant hyperthermia due to anesthesia |
| T88.3xxA | Malignant hyperthermia due to anesthesia, initial encounter |
Formulary Reference Tool